CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 306 enrolled
Drug / intervention
Spiolto® Respimat®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03003494
NCT03003494N/ACompleted
CompareCT.gov

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

Boehringer Ingelheim·observational·Posted Dec 28, 2016·Updated Sep 30, 2019

In Brief

An observational study evaluating Spiolto® Respimat® for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 306 participants across 28 sites.

Detailed Summary

The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 28, 2016
Enrollment StartJun 6, 2017
Primary CompletionJul 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.5 years ago

Interventions

Spiolto® Respimat®drug

observations taken in a period of approximately 6 weeks